Women Shaping the Dental Lab Field
Meet the women who are driving change and empowering the next generation of leaders in the dental laboratory field.
Lisa Astor
Strategic Healthcare Content Expert | Editorial Leadership | Creative Communications Driver
Riding the Wave of Chemoimmunotherapy: A New Era in Endometrial Cancer Management
According to Brian Slomovitz, MD, “immunotherapy has activity and [provides] a benefit in all women with endometrial cancer.” Slomovitz, division director of gynecologic oncology at Mount Sinai Medical Center, professor of obstetrics and gynecology at Florida International University, and clinical trial lead for uterine cancers at the GOG Foundation, told Targeted Therapies in Oncology that especially for patients with deficient mismatch repair (dMMR) endometrial tumors, immunotherapy has result...
Emerging Frontiers in Immunotherapy: The Promise of NK-Cell Therapies
The landscape of cancer therapy has been witnessing a paradigm shift with the advent of immunotherapy treatments, especially for patients with hematologic malignancies. This special feature explores a novel immunotherapy approach for treating patients with cancer.
New HER2-Low Subgroup Expands Utility of HER2-Targeted Therapies
One of the biggest shifts in the oncology field from the past year was the introduction of HER2-low into clinical practice. Patients with breast cancer have typically been divided by subtype according to HER2 positivity or negativity, but emerging evidence suggests that there is now room and treatment options available for a third group of patients that was previously ignored, those characterized with HER2-low disease.HER2 positivity is considered overexpression of HER2 as assessed by an immunoh...
Bispecifics vs CAR T-Cell Therapy: Which Is Better in Relapsed/Refractory Multiple Myeloma?
Newer treatment modalities are changing the landscape for patients with relapsed or refractory multiple myeloma who have received multiple prior therapies. Chimeric antigen receptor (CAR) T-cell therapy is one such newer class of therapy to be introduced into the treatment paradigm for multiple myeloma, and bispecific antibodies are the expected next class of treatments to emerge in the clinic. As such, many questions remain about the optimal sequence and usage of these agents across the course o...
FDA Cracks Down on Dangling Accelerated Approvals in 2021, Pathway Is Scrutinized
This article explores how 10 immunotherapy indications came under question in 2021 after failing to demonstrate clinical benefits in confirmatory trials. Learn about the FDA's tightened oversight and its impact on the availability of certain immunotherapy treatments in the US market, highlighting the delicate balance between rapid access to promising therapies and ensuring proven clinical efficacy.
Avoiding the Chemo Chair
Discover how the groundbreaking TAILORx trial is changing breast cancer care. Learn about the study's findings that allow some patients to safely avoid chemotherapy, leading to gentler treatments without compromising survival rates. This patient-friendly guide explains the implications of these results for individuals facing breast cancer decisions and their caregivers.
Persistence Paved the Path of Discovery for an Immunotherapy Pioneer
Profile of immunotherapy pioneer, Thomas F. Gajewski, MD, PhD, in honor of his induction into the Giants of Cancer Care.